Daratumumab - Save Up to 90% with Coupons, Discounts & Assistance Programs

Daratumumab is available as a 100 mg/5 mL and 400 mg/20 mL injection for IV use.

Daratumumab is an anti-CD38 monoclonal antibody and is used for the following:

Multiple myeloma:

• Given alone or in combination with certain other medications for people who haven’t responded well to previous treatments
• Given in combination with certain medications (other medications differ for people who can and can’t receive a stem-cell transplant)

Daratumumab is an anti-CD38 monoclonal antibody. It treats multiple myeloma by targeting a specific protein called CD38 on the cells’ surface. Many cells, including healthy cells, have this protein. But multiple myeloma cells just have more of them. By binding to this protein, Daratumumab attacks and kills the cancer cells, and also signals to the immune system to do the same. As a result, multiple myeloma cells can’t grow and spread as well.

• Daratumumab is given as an infusion into the veins (IV) by a healthcare provider in a hospital or clinic setting. Your provider will determine your dose based on your body weight
• Adults: When Daratumumab is given alone, the typical dose is 16 mg/kg once a week for 8 doses, then every 2 weeks for 8 doses, then every 4 weeks thereafter
• When Daratumumab is given together with other anticancer medications, your provider will determine your dose and how often you receive it based on what medication combination you’re taking

Daratumumab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Daratumumab:

• Lower white blood cell counts
• Lower platelet counts
• Infusion-related reactions
• Lower red blood cell counts
• Tiredness
• Nausea
• Back pain
• Cough
• Fever
• Upper respiratory tract infections

Serious side effects are rare with Daratumumab. Contact your healthcare provider immediately if you experience any of the following.

• Serious reaction during infusion: fever, headache, stuffy nose, sore throat, cough, trouble breathing, fast heart beat, changes in blood pressure, chills, itching, rash, blurry or changes in vision
• Serious infections (from low white blood cell levels): fever, headache, sore throat, cough, body aches, chills, weakness, tiredness

• There are no major drug interactions listed for Daratumumab. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking

Various FDA-approved generic manufacturers

Based on the mechanism of action, Daratumumab can cause fetal harm when administered to a pregnant woman. Women should use effective contraception during treatment with Daratumumab and for 3 months after the last dose.

• Darzalex